share_log

Blueprint Medicines | 8-K: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT ® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

SEC ·  May 2, 2024 19:13
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more